July 24, 2013Open Access
View Full PaperRiociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Key Points
- To evaluate the effectiveness of riociguat in improving exercise capacity and reducing pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension.
- Participants received riociguat treatment.
Structured PICO
Does riociguat improve exercise capacity and pulmonary vascular resistance in patients with chronic thromboembolic pulmonary hypertension?
P
Population
Patients with chronic thromboembolic pulmonary hypertension
I
Intervention
Riociguat
O
Outcome
Exercise capacity and pulmonary vascular resistancesurrogate
Riociguat provides significant improvements in functional and hemodynamic surrogate markers for patients with chronic thromboembolic pulmonary hypertension.
Abstract
Riociguat significantly improved exercise capacity and pulmonary vascular resistance in patients with chronic thromboembolic pulmonary hypertension. (Funded by Bayer HealthCare; CHEST-1 and CHEST-2 ClinicalTrials.gov numbers, NCT00855465 and NCT00910429, respectively.)